CDT Equity Inc.

CDT Equity Inc. is a publicly traded, data-driven biopharmaceutical development company headquartered in Naples, Florida. The company focuses on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Its mission is to create shareholder value through licensing, strategic mergers and acquisitions, and by positioning itself as a platform for transformative innovation in the biopharmaceutical sector.

CDT Equity leverages artificial intelligence (AI), solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's business model emphasizes value creation through intellectual property and out-licensing, rather than traditional capital-intensive drug development. It identifies clinically validated or underutilized pharmaceutical assets, enhancing them through proprietary solid-form and cocrystallization technologies to generate new compositions of matter. Its pipeline includes candidates targeting autoimmune diseases, idiopathic male infertility, oncology, dermatology, rare diseases, and animal health, with specific assets like AZD1656 and AZD5904 having completed Phase I trials.

In recent developments, CDT Equity Inc. announced a 1-for-25 reverse stock split effective March 26, 2026, and filed new patent applications for its tapinarof intellectual property portfolio. The company also approved a significant investment in Sarborg, an agentic signature intelligence business, and is shifting towards out-license deals with disease-specific partners. Led by CEO Andrew Regan, CDT Equity utilizes AI and algorithmic approaches to analyze thousands of diseases for drug repurposing, aiming for a lean operating structure and capital-efficient approach in its market positioning.